Next generation antibody treatments for ovarian cancer

卵巢癌的下一代抗体治疗

• 批准号: 48937
• 金额: $ 44.41万
• 依托单位: EPSILOGEN LTD
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=48937
• 关键词: Next; generation; antibody; treatments; ovarian

IGEM Therapeutics Ltd aims to develop new platform technologies for creating therapeutic IgE molecules with enhanced anti-tumour activities. The Fc region of IgE has been engineered to introduce additional functionality with a view to improving anti-tumour responses, in particular for treatment of solid tumours. An immediate output of the project will be a FRa-targeting variant IgE antibody with superior anti-cancer activity. It is expected that a cohort of ovarian cancer patients who are presently poorly served by targeted therapies will be early beneficiaries of such a modality. More generally, the project addresses the pressing need to provide better outcomes for patents with solid tumours. IGEM aims to attain a leading position in the global immune-oncology market which is forecast to reach $28 billion by 2025\.

IGEM Therapeutics Ltd 旨在开发新的平台技术，用于创建具有增强抗肿瘤活性的治疗性 IgE 分子。 IgE 的 Fc 区经过改造引入了额外的功能，以改善抗肿瘤反应，特别是实体瘤的治疗。该项目的直接成果将是一种具有卓越抗癌活性的 FRa 靶向变体 IgE 抗体。预计目前靶向治疗效果不佳的卵巢癌患者群体将成为这种疗法的早期受益者。更广泛地说，该项目解决了为实体瘤专利提供更好结果的迫切需要。 IGEM 的目标是在全球免疫肿瘤市场取得领先地位，预计到 2025 年该市场将达到 280 亿美元。